Skip to Content
Merck

Key Documents

View All Documentation

SML2259

Lapatinib

≥98% (HPLC), EGFR/ErbB1 and HER2/ErbB2 inhibitor, powder

Synonym(s):

Lapatinib, GD 2016, GSK 572016, GW-572016, GW572016, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C29H26ClFN4O4S
CAS Number:
231277-92-2
Molecular Weight:
581.06
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD09264194
Assay:
≥98% (HPLC)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Lapatinib, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChI key

BCFGMOOMADDAQU-UHFFFAOYSA-N

Gene Information

human ... EGFR(1956), ERBB2(2064)

Biochem/physiol Actions

Lapatinib acts as a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). It competes for its binding site on the tyrosine kinase domain with adenosine triphosphate (ATP). Lapatinib mediates has been studied in vitro in the inhibition of cell growth as well as and apoptosis induction in several human cancer cells such as breast, lung, vulva, gastric, and head and neck cancer.

Still not finding the right product?

Explore all of our products under Lapatinib

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000468779
0000144063
0000468779
0000144063
0000162120

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lapatinib in breast cancer
Bilancia D, et al.
Annals of Oncology, 18, vi26-vi30 (2007)
Dongwei Zhang et al.
Molecular cancer therapeutics, 7(7), 1846-1850 (2008-07-23)
Epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2/neu), members of the ErbB receptor tyrosine kinase family, are frequently overexpressed in breast cancer and are known to drive tumor growth and progression, making them promising targets for cancer therapy. Lapatinib is
Egle Avizienyte et al.
The Biochemical journal, 415(2), 197-206 (2008-07-01)
Recent clinical data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance
View All Related Papers